Kongressdetails

Hannah Barrs: hannah.barrs@eacr.org

This conference offers a holistic understanding of circulating nucleic acids

(ctDNA/cfDNA) and ctDNA-/cfDNA-based liquid biopsies. It will cover the current and

potential utility of these molecules, how they are built into clinical trial designs to inform

patient management, and the multiple measurements required to gain the most

information from a blood sample. The discussion will feature examples from breast, lung,

colorectal, and bladder cancers. We will review the opportunities and challenges of early

cancer detection with minimally invasive approaches and scan the near and far horizon for

next generation technologies for liquid biopsy.

The target audience for this conference is:

• senior and junior academic clinicians/trialists

• translational scientists

• lab analysts and technology developers in academic, pharma, and biotech sectors